<DOC>
	<DOC>NCT01428765</DOC>
	<brief_summary>This study constitutes Phase I of the Registry Program. The main objective of this study is to characterize the newly diagnosed non-valvular AF patient population at risk for stroke and the selection of antithrombotic treatment for stroke prevention in a real-world setting before dabigatran etexilate is approved for the prevention of strokes and systemic emboli in patients with non-valvular AF in different regions of the world.</brief_summary>
	<brief_title>GLORIA-AF Registry Program (Phase I)</brief_title>
	<detailed_description>Study Design: cross-sectional</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Inclusion criteria: 1) Patients newly diagnosed with nonvalvular atrial fibrillation at risk for stroke. Exclusion criteria: 1. Presence of any mechanical heart valve, or valve disease that is expected to require valve replacement intervention; 2. Patients who have received more than 60 days of oral anticoagulant treatment (vitamin K antagonist) (VKA) in their lifetime; 3. Atrial fibrillation (AF) with a generally reversible cause; 4. Patients with a medical condition other than atrial fibrillation for which chronic use of an oral anticoagulant (VKAs) is indicated</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>